EE536 Cost-Effectiveness of Axicabtagene Ciloleucel (axi-cel) Vs Standard of Care for Adult Patients with Relapsed or Refractory Follicular Lymphoma as 4TH or Later Line Treatment in Sweden
| Autor: | Eklund, O., Hedlöf Kanje, V., Doble, B., Cervin, K. |
|---|---|
| Zdroj: | In Value in Health December 2023 26(12) Supplement:S155-S155 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect